Bio-Techne TECH Cash Flow Statement
| TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | $131.67M-35.1% | ||
| $100.33M-9.5% | $103.73M-6.2% | $106.11M-4.7% | $109.9M-1.6% | $110.85M+0.2% | ||
| $40.69M-6.1% | $41.58M+3.7% | $42.33M+11.0% | $40.83M+7.3% | $43.35M+39.9% | ||
| —— | —— | -$40.49M-22.0% | -$51.11M-29.6% | -$28.38M+22.9% | ||
| —— | $22.55M+37.9% | $29.51M+150% | $18.32M+28.9% | $16.33M+49.1% | ||
| —— | -$22.03M— | —— | —— | —— | ||
| —— | —— | $1.55M-76.2% | $15.41M+22.1% | $17.46M+226% | ||
| —— | —— | —— | —— | —— | ||
| —— | $10.71M— | —— | —— | —— | ||
| —— | —— | -$12.75M— | $8.47M— | -$18.51M— | ||
| —— | —— | —— | —— | —— | ||
| -$20.94M— | —— | —— | —— | —— | ||
| $294.86M+11.3% | $249.32M-18.2% | $251.25M-17.2% | $287.56M-3.8% | $264.85M-13.7% | ||
| $25.26M-42.7% | $26.3M-47.8% | $27.2M-53.5% | $31.01M-50.7% | $44.1M-20.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$11.13M+74.9% | -$14.19M+72.7% | -$13.3M+81.2% | -$35.59M+82.5% | -$44.4M+77.7% | ||
| $49.82M-1.6% | $49.88M-1.5% | $50.15M-0.6% | $50.39M-0.1% | $50.63M+0.5% | ||
| —— | —— | —— | —— | —— | ||
| $196M+102% | $144M-2.0% | $104M-49.3% | $77M-69.9% | $97M-52.9% | ||
| $64.42M-5.9% | $49.33M-31.4% | $50.13M-30.0% | $51.74M-15.1% | $68.45M+47.5% | ||
| $10.88M+62.6% | $11.01M+67.7% | $10.77M+62.5% | $6.52M-70.2% | $6.69M-68.9% | ||
| -$226.36M-1.3% | -$251.69M-21.1% | -$286.54M-39.4% | -$253.91M-107% | -$223.55M— | ||
| —— | —— | $5.6M— | $11.93M— | —— | ||
| $69.15M— | -$4.67M— | —— | —— | —— | ||
| —— | —— | —— | —— | $16.34M+9.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $21.31M— | $12.6M— | ||
| $772K+180% | $922K+143% | $858K+121% | $938K+114% | -$968K+84.7% | ||
| —— | —— | —— | $751K+3.0% | $733K— | ||
| -$20.94M— | —— | —— | —— | —— | ||
| —— | —— | $1.55M-76.2% | $15.41M+22.1% | $17.46M+226% | ||
| —— | $10.71M— | —— | —— | —— | ||
| -$2.44M-585% | -$1.59M-241% | -$672K-140% | $685K-62.6% | $502K-79.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $7.29M+4.2% | $7.22M+114% | ||
| —— | —— | $5.6M— | $11.93M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $269.6M+22.1% | $223.02M-12.3% | $224.06M-8.6% | $256.55M+8.7% | $220.76M-12.1% | ||
| $269.6M+22.1% | $223.02M-12.3% | $224.06M-8.6% | $256.55M+8.7% | $220.76M-12.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bio-Techne generate?
- Bio-Techne (TECH) generated $294.9M in operating cash flow over the trailing twelve months.
- What is Bio-Techne's free cash flow?
- After $25.3M of capital expenditures, Bio-Techne's free cash flow was $269.6M over the trailing twelve months, up 22.1% year over year.
- Where does Bio-Techne's cash flow data come from?
- Every line is extracted from Bio-Techne's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
